DUBLIN, Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
Piper Sandler 35th Annual Healthcare Conference
Date/Time: Tuesday, Nov. 28, 2023 at 11:00 a.m. ET (4:00 p.m. GMT)
6th Annual Evercore ISI HealthCONx Conference
Date/Time: Wednesday, Nov. 29, 2023 at 10:00 a.m. ET (3:00 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
| Last Trade: | US$24.68 |
| Daily Change: | 0.24 0.98 |
| Daily Volume: | 968,493 |
| Market Cap: | US$4.180B |
April 24, 2024 February 15, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
